Smith & Nephew (LON:SN) Price Target Raised to GBX 1,300 at Berenberg Bank

Key Points

• Berenberg Bank raised the price target for Smith & Nephew (LON:SN) from GBX 1,100 to GBX 1,300, while maintaining a "hold" rating on the stock.
• JPMorgan Chase increased their price target to GBX 1,438 with an "overweight" rating, while Deutsche Bank also raised their target to GBX 1,400, retaining a "hold" rating.
• Smith & Nephew shares opened at GBX 1,344.50 and have a market capitalization of £14.74 billion, with a P/E ratio of 48.41.

Smith & Nephew (LON:SN - Get Free Report) had its price target upped by analysts at Berenberg Bank from GBX 1,100 ($14.79) to GBX 1,300 ($17.48) in a research note issued to investors on Thursday, MarketBeat.com reports. The firm currently has a "hold" rating on the stock. Berenberg Bank's target price indicates a potential downside of 3.02% from the stock's current price.

A number of other equities analysts have also recently issued reports on SN. Deutsche Bank Aktiengesellschaft increased their price target on Smith & Nephew from GBX 1,300 ($17.48) to GBX 1,400 ($18.83) and gave the stock a "hold" rating in a report on Wednesday. JPMorgan Chase & Co. increased their price target on Smith & Nephew from GBX 1,357 ($18.25) to GBX 1,438 ($19.34) and gave the stock an "overweight" rating in a report on Wednesday.

Smith & Nephew Trading Down 0.3%

SN stock traded down GBX 4 ($0.05) during trading on Thursday, hitting GBX 1,340.50 ($18.03). The company had a trading volume of 2,497,253 shares, compared to its average volume of 343,671. The stock has a 50 day moving average price of GBX 1,129.06 and a 200-day moving average price of GBX 1,080.06. The firm has a market cap of £14.70 billion, a PE ratio of 48.26, a PEG ratio of 0.46 and a beta of 0.62. The company has a debt-to-equity ratio of 70.22, a quick ratio of 0.84 and a current ratio of 2.51.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.